Biologics for nasal polyps
Dupilumab and other biologics for chronic rhinosinusitis with nasal polyps.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 15, 19, 23, 20, 18.
New guidelines and consensus this year
- Advances in the management of chronic rhinosinusitis with nasal polyps. Review of multidisciplinary strategies and innovations in biological treatmentsActa Otorrinolaringol Esp (Engl Ed)2026 May-Jun
All papers from the last 12 months
522 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative reviewHum Vaccin Immunother2026 DecPMID 42234701Review
- Beyond biomarkers: the role of clinical factors associated with biologic therapy response in severe asthmaAnn Med2026 DecPMID 41672447
- Identification of severe eosinophilic asthma in patients with chronic rhinosinusitis and nasal polyps who are awaiting sinus surgeryJ Allergy Clin Immunol Glob2026 NovPMID 42733480
- Postoperative Recurrence of Chronic Rhinosinusitis with Nasal Polyps: Endotype Mechanisms, Predictive Models, and Novel Strategies for Precision TreatmentInt Arch Allergy Immunol2026 Oct 15PMID 42879369Review
- Pocket guide Biologics in upper and lower airway diseases 2026 by EUFOREARhinology2026 Oct 15PMID 42878116
- A Bibliometric Analysis of Research Interest in Dupilumab for Chronic Rhinosinusitis With Nasal PolyposisPerm J2026 Oct 15PMID 42876213Review
- Second-line dupilumab after anti-IL5/Rα failure: remission rates and clinical outcomes in severe asthmaJ Allergy Clin Immunol Pract2026 Oct 14PMID 42874915
- Efficacy and safety of tezepelumab in Japanese patients with chronic rhinosinusitis with nasal polyps: A subpopulation analysis of the randomized WAYPOINT studyAuris Nasus Larynx2026 Oct 13PMID 42868896
- Sustained clinical control after intranasal corticosteroid withdrawal in chronic rhinosinusitis with nasal polyps (CRSwNP) treated with dupilumabEur Arch Otorhinolaryngol2026 Oct 13PMID 42867640
- Surgery and/or biologics in chronic rhinosinusitis with nasal polyps: EUFOREA/EPOS consensus paperRhinology2026 Oct 10PMID 42858259
More otorhinolaryngology trends
All specialties →Vestibular migraine
Diagnosis and treatment of vestibular migraine.
Gene therapy for hearing loss
Gene therapy for genetic deafness, such as OTOF mutations.
Hearing loss and dementia
Hearing loss, hearing aids and cognitive decline.
Hypoglossal nerve stimulation
An implanted stimulator for obstructive sleep apnoea.
Key point: In France, hypoglossal nerve stimulation is indicated for non-obese moderate-to-severe OSAHS patients with CPAP or MAD failure or contraindications after mandatory DISE.
Tinnitus
Tinnitus mechanisms and treatments, including neuromodulation.
Cochlear implants
Cochlear implantation, including in older adults and single-sided deafness.
Key point: Cochlear implant indications now include profound unilateral or bilateral sensorineural hearing loss, unilateral deafness, or residual hearing, determined individually for each ear.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("chronic rhinosinusitis"[tiab] OR "nasal polyp*"[tiab]) AND (biologic*[tiab] OR dupilumab[tiab] OR mepolizumab[tiab] OR omalizumab[tiab] OR tezepelumab[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.